Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

Impel Pharmaceuticals Inc.

Impel Pharmaceuticals is focused on developing and providing transformative therapies for people suffering from diseases with high unmet needs across various disease areas in addition to the central nervous system (CNS), through the pioneering of an optimized approach to drug delivery. We offer and develop treatments that pair the Company’s proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. 

Impel Pharmaceuticals

Summer is a tough time of year for #migraine and #headaches. To best celebrate #freedom with your friends and family, be mindful of your triggers and keep your acute meds on hand.
 
Wishing everyone a safe and happy #IndependenceDay!

Trudhesa® (DHE mesylate) delivers a trusted #migraine therapeutic to the vascular-rich upper nasal space via the POD® device developed by our co-founder, CTO & CDO, John Hoekman. This results in IV-like efficacy at home - not via injection in an ER.

The Impel team proudly supports the #migraine community. Today we're wearing our #ShadesForMigraine to raise awareness about this complex, neurological disease that's more than just a #headache. 

#MHAM #MigraineAwareness

A second poster on preliminary real-world data underscores the need for non-oral treatment options for #migraine given the prevalence of pre-existing #gastrointestinal disorders among those prescribed with Trudhesa® (DHE mesylate).

See abstract P-160 in Headache: https://lnkd.in/eV8n_mNw

Read our press release to learn more: https://lnkd.in/eEkwReSh

#MHAM Dr. Sheena Aurora

Preliminary real-world data at #AHSAM suggest that concomitant preventive & acute medication use generally decreases in patients taking Trudhesa® (DHE mesylate) nasal spray, and that use of antinausea medications (common with DHE administered via IV) did not increase.

See abstract P-161 in Headache: https://lnkd.in/eV8n_mNw

Read yesterday's press release to learn more: https://lnkd.in/eEkwReSh 

#Migraine #MHAM Zubair Ahmed

	Dec '19	Dec '20	Dec '21	Dec '22
revenue			668K -	12.65M 1,794.01%
cost of revenue			691K -	6.50M 839.94%
gross profit			-23K -	6.16M 26,869.57%
selling and marketing expenses
general and administrative expenses	12.75M -	18.05M 41.52%	50.90M 182.01%	77.89M 53.02%
selling general and administrative expenses	12.75M -	18.05M 41.52%	50.90M 182.01%	77.89M 53.02%
research and development expenses	28.81M -	27.29M 5.30%	20.56M 24.64%	11.46M 44.29%
other expenses	-680K -	-408K 40%	-5.05M 1,137.25%	-9.29M 84.09%
cost and expenses	41.57M -	45.33M 9.07%	72.15M 59.16%	95.84M 32.82%
operating expenses	41.57M -	45.33M 9.07%	71.46M 57.64%	89.34M 25.02%
interest expense				13.84M -
ebitda	-40.84M -	-44.26M 8.36%	-71.49M 61.52%	-83.18M 16.36%
operating income	-41.57M -	-45.33M 9.07%	-71.49M 57.69%	-83.18M 16.36%
depreciation and amortization	722K -	1.08M 49.17%	1.09M 1.02%	1.20M 10.39%
total other income expenses net	-263K -	-463K 76.05%	-5.05M 990.28%	-23.13M 358.16%
income before tax	-41.83M -	-45.80M 9.49%	-76.53M 67.12%	-106.31M 38.91%
income tax expense	30K -	1K 96.67%	2K 100%	23.13M 1,156,300%
net income	-41.86M -	-45.80M 9.41%	-76.54M 67.12%	-129.44M 69.12%
weighted average shs out	13.14M -	13.14M 0%	14.60M 11.12%	23.45M 60.58%
weighted average shs out dil	13.14M -	13.14M 0%	14.60M 11.12%	23.45M 60.58%
eps	-3.19 -	-3.49 9.40%	-5.24 50.14%	-5.52 5.34%
epsdiluted	-3.19 -	-3.49 9.40%	-5.24 50.14%	-5.52 5.34%

COM:IMPELPHARMA

Impel Pharmaceuticals Inc.

Last Close

0.06

20/12 20:58

Market Cap

956K

Beta: -

Volume Today

720.03K

Avg: -

Preview